MA32056B1 - Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene - Google Patents

Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene

Info

Publication number
MA32056B1
MA32056B1 MA33054A MA33054A MA32056B1 MA 32056 B1 MA32056 B1 MA 32056B1 MA 33054 A MA33054 A MA 33054A MA 33054 A MA33054 A MA 33054A MA 32056 B1 MA32056 B1 MA 32056B1
Authority
MA
Morocco
Prior art keywords
ibuprofen
suspension containing
oral pharmaceutical
pharmaceutical suspension
containing paracetamol
Prior art date
Application number
MA33054A
Other languages
Arabic (ar)
English (en)
Inventor
Hartley Atkinson
Austin Kiely
Original Assignee
Wockhardt Research Center
Austin Kiely
Hartley Atkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center, Austin Kiely, Hartley Atkinson filed Critical Wockhardt Research Center
Publication of MA32056B1 publication Critical patent/MA32056B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène. L'invention porte également sur un procédé de traitement d'une douleur péri-opératoire ou postopératoire par administration à un sujet d'une quantité thérapeutiquement efficace d'une suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène.
MA33054A 2008-01-03 2010-08-02 Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene MA32056B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/000005 WO2009083759A1 (fr) 2008-01-03 2008-01-03 Suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène

Publications (1)

Publication Number Publication Date
MA32056B1 true MA32056B1 (fr) 2011-02-01

Family

ID=39521691

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33054A MA32056B1 (fr) 2008-01-03 2010-08-02 Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene

Country Status (12)

Country Link
US (1) US20110124730A1 (fr)
EP (1) EP2231138A1 (fr)
JP (1) JP2011508768A (fr)
KR (1) KR20110065417A (fr)
CN (1) CN102006867A (fr)
AU (1) AU2008345456A1 (fr)
BR (1) BRPI0821871A2 (fr)
CA (1) CA2711211A1 (fr)
MA (1) MA32056B1 (fr)
MX (1) MX2010007358A (fr)
WO (1) WO2009083759A1 (fr)
ZA (1) ZA201004650B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977672B2 (ja) * 2009-04-27 2016-08-24 ラボラトリオ デ アプリカシオネス ファルマコディナミカス，エセ．アー．Ｌａｂｏｒａｔｏｒｉｏ Ｄｅ Ａｐｌｉｃａｃｉｏｎｅｓ Ｆａｒｍａｃｏｄｉｎａｍｉｃａｓ，Ｓ．Ａ． イブプロフェンリシナートの経口投与用の懸濁液
CN101991531B (zh) * 2010-11-09 2012-06-27 武汉人福药业有限责任公司 布洛芬口服混悬液及其制备方法
WO2013025449A1 (fr) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Utilisation de matrice inorganique et de combinaisons de polymères organiques pour la préparation de dispersions amorphes stables
FR2999934B1 (fr) * 2012-12-21 2015-02-20 Servier Lab Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
WO2014102801A1 (fr) * 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Utilisation de compositions d'alginate en prévention ou réduction d'une atteinte hépatique provoquée par un agent hépatotoxique
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN103961312A (zh) * 2014-05-26 2014-08-06 王学重 一种扑热息痛口服液及其制备方法
WO2016008546A1 (fr) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Formulation aqueuse comprenant du paracétamol et de l'ibuprofène
DE102016203146A1 (de) 2016-02-26 2017-08-31 Ivoclar Vivadent Ag Antibakterielle Mundpflegegele
CN106361695B (zh) * 2016-08-26 2017-12-19 湖北唯森制药有限公司 一种右旋布洛芬的研磨方法及其混悬液的制备方法
WO2018192664A1 (fr) 2017-04-20 2018-10-25 Hyloris Developments Sa Procédé de préparation d'une composition à faible teneur en oxygène dissous, comprenant de l'acétaminophène, et éventuellement un ou plusieurs ains, et une composition obtenue à partir de celui-ci
AU2018300075B2 (en) * 2017-07-10 2024-02-29 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
KR20250057925A (ko) 2018-01-11 2025-04-29 켄타우루스 테라퓨틱스 질병 치료를 위한 디하이드로세라마이드 불포화화효소의 저해제
KR101926853B1 (ko) * 2018-04-13 2018-12-07 보령제약 주식회사 약학적 조성물
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
KR102145022B1 (ko) * 2018-08-14 2020-08-14 동아제약 주식회사 이부프로펜의 현탁액 조성물 및 투여 제형
MA58173B1 (fr) * 2019-12-23 2024-03-29 Nutra Essential Otc S L Composition liquide comprenant de l'ibuprofène et de la phényléphrine
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
EP4456884A4 (fr) * 2021-12-28 2025-12-10 Mark Robert Zonfrillo Méthodes et trousses de traitement de la fièvre chez les enfants à l'aide d'une combinaison d'ibuprofène et d'acétaminophène
KR20260020463A (ko) 2023-06-02 2026-02-11 이울리아 츠에티 이부프로펜을 포함하는 약학 조성물
WO2026073874A1 (fr) * 2024-10-02 2026-04-09 Farmalíder, S.A. Solution orale d'arginate d'ibuprofène

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109281A1 (fr) * 1982-11-15 1984-05-23 The Upjohn Company Compositions contenant du flurbiprofen ou de l'ibuprofen
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
JP5630943B2 (ja) * 2004-07-07 2014-11-26 エイ・エフ・ティ・ファーマスーティカルズ・リミテッドＡｆｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 複合剤組成物
ZA200803566B (en) * 2005-12-12 2009-10-28 Adcock Ingram Ltd Pharmaceutical compositions
CN101563074B (zh) * 2006-10-20 2012-11-07 麦克内尔-Ppc股份有限公司 乙酰氨基酚/布洛芬组合

Also Published As

Publication number Publication date
CN102006867A (zh) 2011-04-06
CA2711211A1 (fr) 2009-07-09
BRPI0821871A2 (pt) 2015-06-16
MX2010007358A (es) 2011-05-25
ZA201004650B (en) 2011-09-28
JP2011508768A (ja) 2011-03-17
WO2009083759A1 (fr) 2009-07-09
US20110124730A1 (en) 2011-05-26
AU2008345456A1 (en) 2009-07-09
KR20110065417A (ko) 2011-06-15
EP2231138A1 (fr) 2010-09-29

Similar Documents

Publication Publication Date Title
Preshaw Host modulation therapy with anti‐inflammatory agents
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA34474B1 (fr) Agonistes de gpr40
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
TN2009000138A1 (fr) Biaryl-ether-urees
MA46430B1 (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
TW200806299A (en) Treatment of pain
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
MA33299B1 (fr) Nouvelle formulation de naproxène
MX360289B (es) Composiciones de tapentadol.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MA32904B1 (fr) Composes de purine
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA32798B1 (fr) Acides naphtylacétiques
EP2043637A4 (fr) Procédés et médicaments destinés à l'administration d'ibuprofène